How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (Support establishing an exception to medication step-therapy protocol in specified cases).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY via MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
2026 · third_quarter · Q3
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Source: Senate LDA
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (Support establishing an exception to medication step-therapy protocol in specified cases).
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Break Up Big Medicine Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Break Up Big Medicine Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Break Up Big Medicine Act
Client: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · Firm: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (Support establishing an exception to medication step-therapy protocol in specified cases).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
ROCR Value Based Program Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Seniors’ Access to Critical Medications Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Clinical Trial Modernization Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
FORCE Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
FORCE Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Community Paramedicine Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Community Paramedicine Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Community Paramedicine Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Community Paramedicine Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Impacts and Outcomes for Health Career Training Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act
Impacts and Outcomes for Health Career Training Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Impacts and Outcomes for Health Career Training Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Whole-Home Repairs Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Whole-Home Repairs Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Stop CCP Money Laundering Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Stop CCP Money Laundering Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Improving Seniors’ Timely Access to Care Act of 2025
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Strengthening Medicare for Patients and Providers Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Strengthening Medicare for Patients and Providers Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Medicare Patient Access to Cancer Treatment Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Medicare Patient Access to Cancer Treatment Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Safe Step Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Improving Seniors’ Timely Access to Care Act of 2021
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Saving Access to Laboratory Services Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Strengthening Medicare for Patients and Providers Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY via MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
2026 · second_quarter · Q2
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (Support establishing an exception to medication step-therapy protocol in specified cases).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY via MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
2026 · first_quarter · Q1
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
H.R.5376 The Inflation Reduction Act.
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
H.R.5376 The Inflation Reduction Act.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
H.R.5376 The Inflation Reduction Act.
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
IRA implementation issues
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Pandemic Response; Biden Cancer Moonshot Initiative; H.R.3258 Timely Access to Cancer Treatment Act; H.R.2163, S.464 The Safe Step Act; H.R. 8800 Supporting Medicare Providers Act of 2022; PAHPA reauthorization; Community health center fund reauthorization.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act H.R.5376 The Inflation Reduction Act
H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act. H.R.7213 Pharmacist equitable access, health equity. H.R.6000 Healthcare innovation, ARPA-H, oncology research.
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act H.R.5376 The Inflation Reduction Act
H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act. H.R.7213 Pharmacist equitable access, health equity. H.R.6000 Healthcare innovation, ARPA-H, oncology research.
H.R.7213 Clinical trial diversity, health equity. S.3799 Emergency preparedness and response. H.R.6000 Healthcare innovation, ARPA-H, oncology research. H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act.
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration; H.R.2503; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution; Pharmacy provider status, retail pharmacy. H.R.2759, S.1362.
Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration; Social determinants of health; health disparities in underserved communities, chronic health conditions, H.R.2503;
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Issues related to reimbursement from the Department of Veterans Affairs.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local coverage determination process (S.794); Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014; General Medicare/Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local coverage determination process (S.794)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
H.R.5376 The Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
H.R.5376 The Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R.5376 The Inflation Reduction Act.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; Implementation of the Inflation Reduction Act.
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Healthcare innovation, ARPA-H, oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; Implementation of the Inflation Reduction Act.
H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act; S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act; H.R. 3258 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Pharmacist equitable access, health equity. H.R. 7213 Clinical trial diversity, health equity. H.R. 5030/S. 2706 Emergency preparedness and response. S. 3799 Healthcare innovation, ARPA-H, oncology research. H.R. 6000 Laboratory diagnostic services, schedule reimbursement S. 4449 Omnibus federal appropriations Pandemic Response Biden Cancer Moonshot Initiative H.R.3258 Timely Access to Cancer Treatment Act. H.R.2163, S.464 The Safe Step Act. H.R. 8800 Supporting Medicare Providers Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act. H.R.7213 Pharmacist equitable access, health equity. H.R.6000 Healthcare innovation, ARPA-H, oncology research.
S.1909, H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act H.R.5376 The Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
S.4449 Laboratory diagnostic services, schedule reimbursement. H.R.7213 Pharmacist equitable access, health equity. S.1909,H.R.3554 Pharmacy DIR Reform to Reduce Senior Drug Costs Act. H.R. 3258 Timely Access to Cancer Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution; S.1362; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement from the Department of Veterans Affairs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement from the Department of Veterans Affairs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement from the Department of Veterans Affairs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE